EichorEICHOR
Condition: Ovarian Serous Adenocarcinoma Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Ovarian Serous Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Prospective, Multi-center, Real-world Study of Ovarian Metastatic Colorectal Cancer Patients
Phase N/A · 4 location(s) · West China Hospital · NCT04716257A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Phase N/A · 6 location(s) · Massachusetts General Hospital · NCT04794322A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · 9 location(s) · Apollo Therapeutics Ltd · NCT06399757Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Phase 1/Phase 2 · 16 location(s) · Scancell Ltd · NCT05329532Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Phase N/A · 1 location(s) · Oslo University Hospital · NCT02073500Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Xing Xie · NCT04518501Identifying Genetic Targets in Gynecological Tumors
Phase N/A · 1 location(s) · Azienda USL Reggio Emilia - IRCCS · NCT07169396Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fa
Phase 2 · 3 location(s) · Mayo Clinic · NCT06639074Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Res
Phase 1 · 7 location(s) · National Cancer Institute (NCI) · NCT04585958Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
Phase 3 · 19 location(s) · Ente Ospedaliero Ospedali Galliera · NCT05601700Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo
Phase 1 · 14 location(s) · National Cancer Institute (NCI) · NCT05950464Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade En
Phase 2 · 1 location(s) · University College, London · NCT05080556Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
Phase 2 · 1 location(s) · Sunnybrook Health Sciences Centre · NCT05961124This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT00488878Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05415709Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
Phase 3 · 19 location(s) · M.D. Anderson Cancer Center · NCT04575935Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Phase 2 · 1 location(s) · Emory University · NCT05998135A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Phase 1 · 17 location(s) · NextCure, Inc. · NCT06792552Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.
Phase N/A · 1 location(s) · Jules Bordet Institute · NCT07451483Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT04919629Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1/Phase 2 · 3 location(s) · Mayo Clinic · NCT05920798Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06883487Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
NA · 1 location(s) · Turku University Hospital · NCT04846933Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · 676 location(s) · NRG Oncology · NCT06580314Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Phase 2 · 3 location(s) · Centre Oscar Lambret · NCT05500391
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.